InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,465.71
(
-0.07%
)
US TECH 100
19,187.20
(
0.06%
)
Dow Jones
38,975.67
(
-0.35%
)
Brent Oil
84.58
(
0.47%
)
Bitcoin
61,825.81
(
0.01%
)
Post# of 345981
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

itsabouttime

Send PM Follow Ignore
Followers 16
Posts 1362
Boards Moderated 0
Alias Born 02/06/2014

itsabouttime

Re: None

Tuesday, 06/28/2016 8:06:36 PM

Tuesday, June 28, 2016 8:06:36 PM

Post# of 345981
NCCN

Planned studies include bavituximab in combination with pembrolizumab (AZN) in hepatocellular carcinoma,and durvalumab (MERCK) in NSCLC. Good
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDMO News
More CDMO News
InvestorsHub NewsWire

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM

Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM

Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM

Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM

Start posting your company's news
Only $200 per official company press release!